On Thursday, Banco Santander, S.A. (ADR) (NYSE:SAN)’s shares dwindled -0.95%, and closed at $7.39, as Banco Santander, S.A. (ADR) (SAN), signed a Memorandum of Understanding with Georgetown University, to support a new initiative on the social economy. The initiative will focus on issues of social banking, social finance, and social entrepreneurship. This Memorandum was signed by Ana Botin, Executive Chairman of Banco Santander and John DeGioia, President of Georgetown University.
This initiative will engage Georgetown’s students and faculty together with the Santander network of nearly 1,200 universities and research centers worldwide to conduct research and workshops on issues related to the social economy. The initiative envisions two pillars: a local influence program that engages stakeholders at the local, state, and national levels, and a global pillar in which Georgetown will convene a workshop with students from various Santander Universities around the world to develop programs of social influence.
“The Memorandum we signed recently with Georgetown University, demonstrates how we promote and support initiatives that benefit our communities. The initiative on Social Economy will become a global point of reference on the subject,” said Ana Botin, Executive Chairman of Banco Santander.
Banco Santander, S.A. provides various banking products and services for individuals and companies. The corporation offers various deposit products, such as demand and time deposits; mortgages, auto finance, and personal credits; consumer finance; and mobile banking and electronic banking services.
Celladon Corp (NASDAQ:CLDN)’s shares dropped -2.63%, and settled at $17.06, during the last trading session on Thursday, soon after Celladon Corp (CLDN), declared financial results for the quarter and year ended December 31, 2014 and recent corporate highlights.
Fourth Quarter 2014 and Recent Corporate Highlights
- In February 2015, we reached the last subject’s last visit during the 12 month primary data analysis period in the CUPID2 study, thereby reaching the study’s primary analysis data cutoff. We remain on track to un-blind the data and declare top-line results from this study in late April 2015.
- In December 2014, we commenced work with Novasep, Inc. (Novasep) for the potential future commercial manufacture of MYDICAR drug substance (AAV1/SERCA2a), and in March 2015, we declared the execution of a development, manufacturing and supply contract with Novasep, which, if supported by the CUPID2 data, positions the parties to continue with the process transfer, facility retrofitting, development and manufacturing activities necessary for the future commercial supply of MYDICAR drug substance. If we proceed with the ongoing activities beyond a specified termination period following the un-blinding of CUPID2, we would commit to a multi-year contract for the future commercial supply of MYDICAR drug substance.
Fourth Quarter and Year-End 2014 Financial Results
- Cash Position: Cash, cash equivalents and investments as of December 31, 2014 were $84.9 million.
- Research and Development Expenses: Research and development expenses were $7.2 million and $5.2 million for the fourth quarter of 2014 and 2013, respectively. Research and development expenses were $22.7 million and $16.9 million for the years ended December 31, 2014 and 2013, respectively.
- General and Administrative Expenses: General and administrative expenses were $3.8 million and $0.8 million for the fourth quarter of 2014 and 2013, respectively. General and administrative expenses were $10.3 million and $3.0 million for the years ended December 31, 2014 and 2013, respectively.
- Other Expense, Net: Other expense, net was $0.4 million and $0.2 million for the fourth quarter of 2014 and 2013, respectively. Other expense was $0.8 million and $0.1 million for the years ended 2014 and 2013, respectively.
Celladon Corporation, a clinical-stage biotechnology corporation, focuses on developing cardiovascular gene therapy and calcium dysregulation. The corporation’s lead product candidate comprises MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that result in inadequate pumping of the heart.
At the end of Thursday’s trade, Brandywine Realty Trust (NYSE:BDN)’s shares dipped -2.62%, and closed at $15.21, after Brandywine Realty Trust (BDN), declared that The U.S. Environmental Protection Agency (EPA) has recognized the Corporation with a 2015 ENERGY STAR Partner of the Year – Sustained Excellence Award for continued leadership in protecting our environment through superior energy efficiency achievements. Brandywine’s accomplishments will be recognized in Washington, D.C. on April 20, 2015.
Key accomplishments of Brandywine’s award-winning energy administration program comprise:
- 139 properties (21.5 million square feet) have earned the ENERGY STAR Label
- 4% of the square footage in Brandywine’s 260 owned and managed properties has earned the Label at least once
- In aggregate, counting re-certifications, Brandywine has earned 304 Labels in the past 3 years for our owned and managed properties
“We truly value our partnership with ENERGY STAR and it is an honor to be recognized for the third successive year as an ENERGY STAR Partner of the Year,” said George Johnstone, Executive Vice President – Operations of Brandywine Realty Trust. “Our property administration and engineering teams remain diligent and focused on making our portfolio more energy efficient. These efforts led to 26 new ENERGY STAR Labels and 61 re-certification Labels in 2014.”
Brandywine Realty Trust is a publically owned real estate investment trust. The firm invests in real estate markets of the United States. It makes investments in office, mixed-use, and industrial properties. Brandywine Realty Trust was founded in 1985 and is based in Radnor, Pennsylvania with additional offices in Mount Laurel, New Jersey; Richmond, Virginia; Dallas, Texas; Falls Church, Virginia; Oakland, California; Austin, Texas, and Carlsbad, California.
CubeSmart (NYSE:CUBE), ended its Thursday’s trading session with -2.62% loss, and closed at $23.44, as CubeSmart (CUBE), declared that the Corporation intends to release financial results for the three month period ending March 31, 2015 after the market close on Thursday, April 30, 2015. An accorporationing conference call will be held at 11:00 a.m. ET on Friday, May 1, 2015.
CubeSmart is an equity real estate investment trust. The firm invests in the real estate markets of the United States. It engages in ownership, operation, attainment and development of self-storage facilities. The firm was formerly known as U-Store-It Trust. CubeSmart was founded in July 2004 and is based in Wayne, Pennsylvania.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
